Your browser doesn't support javascript.
loading
Protective Immunity and New Vaccines for Lyme Disease.
Gomes-Solecki, Maria; Arnaboldi, Paul M; Backenson, P Bryon; Benach, Jorge L; Cooper, Christopher L; Dattwyler, Raymond J; Diuk-Wasser, Maria; Fikrig, Erol; Hovius, J W; Laegreid, Will; Lundberg, Urban; Marconi, Richard T; Marques, Adriana R; Molloy, Philip; Narasimhan, Sukanya; Pal, Utpal; Pedra, Joao H F; Plotkin, Stanley; Rock, Daniel L; Rosa, Patricia; Telford, Sam R; Tsao, Jean; Yang, X Frank; Schutzer, Steven E.
Afiliação
  • Gomes-Solecki M; Department of Microbiology, Immunology, and Biochemistry, University of Tennessee Health Science Center, Tennessee, USA.
  • Arnaboldi PM; Department of Microbiology/Immunology, New York Medical College, New York, USA.
  • Backenson PB; New York State Department of Health, Albany, New York, USA.
  • Benach JL; Department of Molecular Genetics and Microbiology, Stony Brook University, New York, USA.
  • Cooper CL; Molecular and Translational Sciences, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA.
  • Dattwyler RJ; Department of Microbiology/Immunology, New York Medical College, New York, USA.
  • Diuk-Wasser M; Department of Ecology, Evolution, and Environmental Biology, Columbia University, New York, USA.
  • Fikrig E; Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
  • Hovius JW; Department of Internal Medicine, Section of Infectious Diseases, Amsterdam Multidisciplinary Lyme Borreliosis Center, Amsterdam University Medical Centers, Academic Medical Center, The Netherlands.
  • Laegreid W; Department of Veterinary Sciences, Wyoming State Veterinary Laboratory, University of Wyoming, Laramie, Wyoming, USA.
  • Lundberg U; Valneva Austria GmbH, Vienna, Austria.
  • Marconi RT; Department of Microbiology and Immunology, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA.
  • Marques AR; Lyme Disease Studies Unit, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Molloy P; Imugen, Norwood, Massachusetts, USA.
  • Narasimhan S; Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
  • Pal U; Department of Veterinary Medicine, University of Maryland, College Park, Maryland, USA.
  • Pedra JHF; Department of Microbiology and Immunology, University of Maryland School of Medicine, Maryland, USA.
  • Plotkin S; Department of Pediatrics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Rock DL; College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Illinois, USA.
  • Rosa P; Laboratory of Bacteriology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
  • Telford SR; Department of Infectious Disease and Global Health, Tufts University, North Grafton, Massachusetts, USA.
  • Tsao J; Department of Fisheries and Wildlife, Michigan State University, East Lansing, Michigan, USA.
  • Yang XF; Departments of Large Animal Clinical Sciences, Michigan State University, East Lansing, Michigan, USA.
  • Schutzer SE; Department of Microbiology and Immunology, Indiana University of School of Medicine, Indianapolis, Indiana, USA.
Clin Infect Dis ; 70(8): 1768-1773, 2020 04 10.
Article em En | MEDLINE | ID: mdl-31620776
ABSTRACT
Lyme disease, caused by some Borrelia burgdorferi sensu lato, is the most common tick-borne illness in the Northern Hemisphere and the number of cases, and geographic spread, continue to grow. Previously identified B. burgdorferi proteins, lipid immunogens, and live mutants lead the design of canonical vaccines aimed at disrupting infection in the host. Discovery of the mechanism of action of the first vaccine catalyzed the development of new strategies to control Lyme disease that bypassed direct vaccination of the human host. Thus, novel prevention concepts center on proteins produced by B. burgdorferi during tick transit and on tick proteins that mediate feeding and pathogen transmission. A burgeoning area of research is tick immunity as it can unlock mechanistic pathways that could be targeted for disruption. Studies that shed light on the mammalian immune pathways engaged during tick-transmitted B. burgdorferi infection would further development of vaccination strategies against Lyme disease.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carrapatos / Doença de Lyme / Vacinas / Ixodes / Borrelia burgdorferi Limite: Animals / Humans Idioma: En Revista: Clin Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carrapatos / Doença de Lyme / Vacinas / Ixodes / Borrelia burgdorferi Limite: Animals / Humans Idioma: En Revista: Clin Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos